Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007

Context: Complete the 3-Year-Cyle (1) Last year of the 3 Year work programme 2007/2009 Commitment to scientific excellence; Commitment to partnership; Commitment to good governance and efficiency. EU action plan New Regulation External evaluation Enlargement and International cooperation remain important

Context: Complete the 3-Year-Cyle (2) Implementation of FONTE More efforts invested in analysis and transversal work New communication strategy and international cooperation strategy New EU Action Plan

2009 Core activities Monitoring and reporting on the drugs phenomenon Routine reporting activities Expert meetings Continue work to identify and disseminate best practices Continue the implementation more professional approach to data management and statistical reporting

Consolidate monitoring – Strategic objectives Continue the work on quality assurance: Continue the revision of the reporting tools according to the same principles adopted in 2007 Strategy for monitoring and reporting on drug treatment More sensitivity to polydrug use and PDU Improve monitoring of supply issues

Selected activities (1) Put into practice minimum implementation standards and criteria for key indicators. Further develop and conceptualise problem drug use and other intensive, long-term and risky patterns of drug use and improve estimation techniques. Continue efforts to apply new estimation techniques both on PDU (problem drug use) prevalence and incidence. Explore solution for monitoring polydrug use, in particular how to better exploit the data that is already collected in existing systems. Carry out critical review of the treatment demand indicator (TDI). Enhance understanding of DRID spread and intervention effectiveness (through modelling).

Selected activities (2) Revise/finalise data-collection instruments and protocols on Social rehabilitation, Alternatives to prison, Policy and institutional framework. Carry out critical review of existing data collection tools in area of drug supply Continue to develop reporting and analytical capacity on EU drug legislation and associated activities. Increase understanding of mortality related to specific opioids (substitution drugs, Fentanyl, etc.) and drug combinations. Audit of the European Cannabis market

Selected activities (3) Carry out the special analyses necessary for 2009 selected issues (Sentencing statistics, Trends in injecting drug use and Polydrug use in Europe). Conduct joint data analysis from general population surveys including psychometric scales to measure intensive forms of cannabis use. Identify the prevention needs of the most vulnerable within a universal programme approach. Maintain and further develop the Best practice portal, the EIB (Evaluation instruments bank) and PERK (Prevention and evaluation resources kit).

Enhanced analysis of data – Specific Products (1) EMCDDA Scientific Monograph Harm reduction Monograph EMCDDA Insights New groups of psychoactive substances in Europe Internet based treatment EMCDDA Selected Issues Sentencing statistics Trends in injecting drug use Polydrug use in Europe EMCDDA Manuals Guidelines for risk assessment of new psychoactive substances Drug profiles (GHB, Ketamine, Methadone, Buprenorphine)

Enhanced analysis of data – Specific Products (2) Drugs in focus – policy briefings Europe’s evolving opiate situation – issues for policy and practice Working with the criminal justice setting – a key area for drug interventions Indiciated prevention and neurobiology Online tools and web-based resources Portal for dissemination of best practice ELDD and legal topic overviews on -Limited quantities of drugs -Drug laws and the internet Key indicator portal Country situation summary

Enhanced analysis of data – Specific Products (3) Conference proceedings Conference website EU drugs legislation in practice (linked publication) Joint publications and contribution to partners’ reports Developing and sustaining a national drugs observatory - with CICAD. A systematic review of drug surveys and methods used in the EU Member States - With Institute for Social Drug Research, Ghent Vulnerable groups and individuals in youth population – in collaboration with NIDA Contribution to the revision of the Addiction Severity Index – in collaboration with UNODC Handbook of economics of illicit drugs Publication 2010 – in collaboration with Paul de Grauwe, University Leuwen

Enhanced analysis of data – Specific Products (3) EMCDDA technical papers and reviews State of implementation of the EMCDDA key epidemiological indicators based on newly defined criteria Drug-related infectious diseases (DRID) revised protocol Mortality cohort study revised protocol Treatment demand indicator (TDI) revised protocol Report on the first results of the extensive data collection on treatment prevalence Update on cannabis markets in Europe Hospital emergency data: conclusion on feasibility (article) Heroin use incidence estimation: comparison of two methods in five European countries Review of IDU estimation in EU countries Modelling hepatitis C trends (articles) Specific analysis on drug-related infectious diseases/injecting drug use/harm reduction (article) Review of available data, potential indicators and options for monitoring strategies in the areas of drug supply and drug supply reduction Guidelines on collecting retail drug prices Estimates of drug consumption Treatment prevalence analysis (article) Gender analysis among treated clients (article) Working/discussion paper on methodology, sources and issues to assess health consequences of non opiate substances use Preliminary results of literature review on epidemiology, risk factors and health impact of non fatal OD

Additional activities Move to the new building Conduct an international conference Products linked to the conference Ongoing: strengthen collaboration with relevant institutional and scientific partners - in particular the Commission, UNODC EUROPOL Pompidou Group